These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 15504162)

  • 1. Immune responsiveness against allogeneic platelet transfusions is determined by the recipient's major histocompatibility complex class II phenotype.
    Sayeh E; Aslam R; Speck ER; Le-Tien H; Lazarus AH; Freedman J; Semple JW
    Transfusion; 2004 Nov; 44(11):1572-8. PubMed ID: 15504162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transfusion-related immunomodulation by platelets is dependent on their expression of MHC Class I molecules and is independent of white cells.
    Aslam R; Speck ER; Kim M; Freedman J; Semple JW
    Transfusion; 2008 Sep; 48(9):1778-86. PubMed ID: 18522705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel immunosuppressive pathway involving peroxynitrite-mediated [corrected] nitration of platelet antigens within antigen-presenting cells.
    Semple JW; Speck ER; Fabron A; Kim RA; Freedman J
    Transfusion; 2008 Sep; 48(9):1917-24. PubMed ID: 18564400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of natural killer cell-mediated bone marrow graft rejection by allogeneic major histocompatibility complex class I, but not class II molecules.
    Ohlén C; Höglund P; Sentman CL; Carbone E; Ljunggren HG; Koller B; Kärre K
    Eur J Immunol; 1995 May; 25(5):1286-91. PubMed ID: 7774631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct evidence for in vivo induction of CD8+ cytotoxic T cells directed to donor MHC class I peptides following mouse allotransplantation.
    Popov IA; Fedoseyeva EV; Orr PL; Garovoy MR; Benichou G
    Transplantation; 1995 Dec; 60(12):1621-4. PubMed ID: 8545902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semi-allogeneic (F1) versus fully allogeneic blood transfusions: differences in their ability to induce specific immunological unresponsiveness.
    Roelen DL; Dover EL; Niimi M; Young NT; Morris PJ; Wood KJ
    Eur J Immunol; 1996 Jul; 26(7):1468-74. PubMed ID: 8766548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-class II antibodies, but not cytotoxic T-lymphocyte antigen 4-immunoglobulin hybrid molecules, prevent rejection of major histocompatibility complex class II-negative myeloma in T-cell receptor-transgenic mice.
    Dembic Z; Hofgaard PO; Omholt H; Bogen B
    Scand J Immunol; 2004; 60(1-2):143-52. PubMed ID: 15238083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indirect allorecognition of platelets by T helper cells during platelet transfusions correlates with anti-major histocompatibility complex antibody and cytotoxic T lymphocyte formation.
    Semple JW; Speck ER; Milev YP; Blanchette V; Freedman J
    Blood; 1995 Jul; 86(2):805-12. PubMed ID: 7606011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Instillation of allogeneic lung antigen-presenting cells deficient in expression of major histocompatibility complex class I or II antigens have differential effects on local cellular and humoral immunity and on pathology in recipient murine lungs.
    Heidler KM; Baker K; Woods K; Schnizlein-Bick C; Cummings OW; Sidner R; Foresman B; Wilkes DS
    Am J Respir Cell Mol Biol; 2000 Oct; 23(4):499-505. PubMed ID: 11017915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apparent split tolerance of CD8+ T cells from beta 2-microglobulin-deficient (beta 2m-/-) mice to syngeneic beta 2m+/+ cells.
    Jhaver KG; Rao TD; Frey AB; Vukmanović S
    J Immunol; 1995 Jun; 154(12):6252-61. PubMed ID: 7759863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donor antigen-presenting cells are important in the development of obliterative airway disease.
    Szeto WY; Krasinskas AM; Kreisel D; Popma SH; Rosengard BR
    J Thorac Cardiovasc Surg; 2000 Dec; 120(6):1070-7. PubMed ID: 11088028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The replacement of graft endothelium by recipient-type cells conditions allograft rejection mediated by indirect pathway CD4+ T cells.
    Kapessidou Y; Habran C; Buonocore S; Flamand V; Barvais L; Goldman M; Braun MY
    Transplantation; 2006 Aug; 82(4):582-91. PubMed ID: 16958183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A major role for host MHC class I antigen presentation for promoting islet allograft survival.
    Beilke J; Johnson Z; Kuhl N; Gill RG
    Transplant Proc; 2004 May; 36(4):1173-4. PubMed ID: 15194406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrosarcoma cells expressing allogeneic MHC Class II antigens induce protective antitumor immunity.
    Leach DR; Callahan GN
    J Immunol; 1995 Jan; 154(2):738-43. PubMed ID: 7814880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta 2-microglobulin-deficient background ameliorates lethal phenotype of the TGF-beta 1 null mouse.
    Kobayashi S; Yoshida K; Ward JM; Letterio JJ; Longenecker G; Yaswen L; Mittleman B; Mozes E; Roberts AB; Karlsson S; Kulkarni AB
    J Immunol; 1999 Oct; 163(7):4013-9. PubMed ID: 10491004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extreme leukoreduction of major histocompatibility complex class II positive B cells enhances allogeneic platelet immunity.
    Semple JW; Speck ER; Cosgrave D; Lazarus AH; Blanchette VS; Freedman J
    Blood; 1999 Jan; 93(2):713-20. PubMed ID: 9885234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allorecognition of isolated, denatured chains of class I and class II major histocompatibility complex molecules. Evidence for an important role for indirect allorecognition in transplantation.
    Dalchau R; Fangmann J; Fabre JW
    Eur J Immunol; 1992 Mar; 22(3):669-77. PubMed ID: 1547813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic recognition of class I molecules: anti-H-2Ld repertoire of H-2b mice includes T cells recognizing mutant class II H-2b (Abm12) molecules.
    Frangoulis B; Urbero B; Pla M
    Eur J Immunol; 1993 Aug; 23(8):1884-8. PubMed ID: 8344350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetically engineered blood pharming: generation of HLA-universal platelets derived from CD34+ progenitor cells.
    Figueiredo C; Blaszczyk R
    J Stem Cells; 2014; 9(3):149-61. PubMed ID: 25157449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
    Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.